Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date
Investigational New Drug (IND) application for ZKN-013 filed for treatment of recessive dystrophic epidermolysis bullosa (RDEB)
https://finance.yahoo.com/news/eloxx-pharmaceuticals-reports-fourth-quarter-120000143.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.